JNK inhibition suppresses microglial NLRP3 activation and oxidative stress but unexpectedly worsens pain in diabetic neuropathy: insights from a combined in vitro and in vivo pharmacological study
{{output}}
Diabetic neuropathy (DN) is driven by neuroinflammation and oxidative stress, with c-Jun N-terminal kinase (JNK) as a key mediator; however, the effects of JNK inhibition on neuropathic pain remain unclear. Therefore, we investigated the therapeutic potential ... ...
